MENU
+Compare
GALT
Stock ticker: NASDAQ
AS OF
Jun 20 closing price
Price
$3.29
Change
-$0.00 (-0.00%)
Capitalization
152.53M

GALT Galectin Therapeutics Forecast, Technical & Fundamental Analysis

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GALT with price predictions
Jun 20, 2025

GALT in upward trend: 10-day moving average moved above 50-day moving average on June 16, 2025

The 10-day moving average for GALT crossed bullishly above the 50-day moving average on June 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 05, 2025. You may want to consider a long position or call options on GALT as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GALT just turned positive on June 03, 2025. Looking at past instances where GALT's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

GALT moved above its 50-day moving average on June 12, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +12 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 165 cases where GALT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GALT moved out of overbought territory on June 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GALT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GALT broke above its upper Bollinger Band on June 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GALT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.740). P/E Ratio (0.000) is within average values for comparable stocks, (59.155). GALT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.273). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.620).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GALT is expected to report earnings to rise 26.67% to -18 cents per share on August 18

Galectin Therapeutics GALT Stock Earnings Reports
Q2'25
Est.
$-0.19
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.04
The last earnings report on May 15 showed earnings per share of -15 cents, beating the estimate of -20 cents. With 4.33M shares outstanding, the current market capitalization sits at 152.53M.
A.I. Advisor
published General Information

General Information

a developer of drugs to combat various diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4960 Peachtree Industrial Boulevard
Phone
+1 678 620-3186
Employees
14
Web
https://www.galectintherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMVIX15.93N/A
N/A
Goldman Sachs Small/Mid Cap Equity Inv
DTCYX19.30-0.04
-0.21%
BNY Mellon Sust US Equity Y
UIVQX12.27-0.04
-0.32%
MFS Intrinsic Value R4
VVONX21.95-0.09
-0.41%
Invesco Value Opportunities R5
WBIRX29.74-0.16
-0.54%
William Blair International Growth R6

GALT and Stocks

Correlation & Price change

A.I.dvisor tells us that GALT and SNPX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GALT and SNPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
-26.44%
SNPX - GALT
32%
Poorly correlated
+4.88%
RNAC - GALT
32%
Poorly correlated
-2.40%
BCAB - GALT
31%
Poorly correlated
+0.73%
ACXP - GALT
28%
Poorly correlated
-23.61%
ERAS - GALT
27%
Poorly correlated
N/A
More

Groups containing GALT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
-26.44%
drugs
theme (240 stocks)
8%
Poorly correlated
-1.29%
biotechnology
theme (226 stocks)
6%
Poorly correlated
-1.25%
diseases
theme (41 stocks)
5%
Poorly correlated
-1.85%